1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Neurological Biomarkers Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Neurological Biomarkers Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Neurological Biomarkers Market Regional Analysis
6.2 Europe Neurological Biomarkers Market Revenue 2017-2027 (US$ Million)
6.3 Europe Neurological Biomarkers Market Forecast Analysis
7. Europe Neurological Biomarkers Market Analysis – by Product
7.1 Proteomics Biomarker
- 7.1.1 Overview
- 7.1.2 Proteomics Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Genomics Biomarker
- 7.2.1 Overview
- 7.2.2 Genomics Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Metabolomics Biomarker
- 7.3.1 Overview
- 7.3.2 Metabolomics Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Imaging Biomarker
- 7.4.1 Overview
- 7.4.2 Imaging Biomarker: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Europe Neurological Biomarkers Market Analysis – by Application
8.1 Alzheimer's Disease
- 8.1.1 Overview
- 8.1.2 Alzheimer's Disease: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Parkinson's Disease
- 8.2.1 Overview
- 8.2.2 Parkinson's Disease: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Schizophrenia
- 8.3.1 Overview
- 8.3.2 Schizophrenia: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.4 Huntington's Disease
- 8.4.1 Overview
- 8.4.2 Huntington's Disease: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.5 Spinal Muscular Atrophy
- 8.5.1 Overview
- 8.5.2 Spinal Muscular Atrophy: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Europe Neurological Biomarkers Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Clinical Diagnostics
- 9.2.1 Overview
- 9.2.2 Clinical Diagnostics: Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Research Organizations
- 9.3.1 Overview
- 9.3.2 Research Organizations : Europe Neurological Biomarkers Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Europe Neurological Biomarkers Market – Europe Analysis
10.1 Overview
10.2 Europe
- 10.2.1 Europe Neurological Biomarkers Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.2.1.1 Europe Neurological Biomarkers Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 UK:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.1.1 UK: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.2.1.1.2 UK: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.2.1.1.3 UK: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.2.1.2 Germany:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.2.1 Germany: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.2.1.2.2 Germany: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.2.1.2.3 Germany: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.2.1.3 France:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.3.1 France: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.2.1.3.2 France: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.2.1.3.3 France: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.2.1.4 Russia:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.4.1 Russia: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.2.1.4.2 Russia: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.2.1.4.3 Russia: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.2.1.5 Italy:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.5.1 Italy: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.2.1.5.2 Italy: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.2.1.5.3 Italy: Europe Neurological Biomarkers Market Breakdown, by End User
- 10.2.1.6 Rest of Europe:
Europe Neurological Biomarkers Market – Revenue and Forecast to 2027 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Neurological Biomarkers Market Breakdown, by Product
- 10.2.1.6.2 Rest of Europe: Europe Neurological Biomarkers Market Breakdown, by Application
- 10.2.1.6.3 Rest of Europe: Europe Neurological Biomarkers Market Breakdown, by End User
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Thermo Fisher Scientific, Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Myriad Genetics
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 QIAGEN
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Abbott
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck KGaA
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Get Free Sample For Europe Neurological Biomarkers Market
